Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.

Patients, doctors and investors will soon learn a lot more about a new ... Eli Lilly's pill better in phase three trials because they are longer in duration than the mid-stage studies and likely ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

The Lilly research was presented Sunday at the annual meeting of the American College of Cardiology and simultaneously published in the New ... the study was “really elegant.” Eli Lilly ...

They have 55 new medicine candidates in clinical ... that is being evaluated in phase 2 studies (ulcerative colitis and Crohn's disease). Eli Lilly has a very strong balance sheet with solid ...